Richard Pazdur, the longtime leader of the U.S. Food and Drug Administration’s oncology division, is set to retire from the agency shortly after beginning his new role. An FDA spokesperson confirmed Pazdur’s decision, stating that his departure will occur “only weeks” into his latest tenure. The circumstances surrounding the abrupt departure have not been publicly detailed.
Pazdur has been a prominent figure within the FDA, particularly known for his influence on cancer drug approvals and his leadership in advancing oncology treatments. He previously served as the director of the FDA’s Oncology Center of Excellence and has held various key positions within the agency over his career. His experience has made him a respected, if sometimes controversial, voice in drug regulation.
The FDA has not announced plans for a successor or formal transition details following Pazdur’s departure. The agency’s spokesperson emphasized that the FDA remains committed to its mission of protecting public health and continuing its regulatory work amid leadership changes. As the situation develops, industry observers and stakeholders will be watching closely to see how Pazdur’s departure impacts the agency’s ongoing initiatives in drug approval and regulation.